Perampanel , a selective , noncompetitive - amino-@-hydroxy-@-methyl-@-isoxazolepropionic acid ( AMPA ) glutamate receptor antagonist , is indicated for adjunctive treatment of partial seizures in patients @years based on three phase III clinical studies .